– Andrew Dickinson Promoted to Executive Vice President, Corporate
Development and Strategy;
Executive Vice President, Strategy, to Leave Gilead at End of August –
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 4, 2018--
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of
Andrew Dickinson to Executive Vice President, Corporate Development and
Strategy, with responsibility for Gilead’s corporate development,
alliance management, competitive intelligence, and corporate strategy
and planning functions, effective immediately. Mr. Dickinson will become
a member of Gilead’s senior leadership team. The company also announced
that Martin Silverstein, Executive Vice President, Strategy, has decided
to leave Gilead at the end of August to return to the East Coast.
Mr. Dickinson joined Gilead in 2016 as Senior Vice President, Corporate
Development. He led the acquisitions of Kite Pharma, Inc. and Cell
Design Labs, Inc., and has been instrumental in reshaping Gilead’s
approach to corporate development, increasing the volume and types of
agreements that the company has entered into during his tenure. Prior to
joining Gilead, Mr. Dickinson served as Global Co-Head of Healthcare
Investment Banking for Lazard. At Lazard, he advised on numerous,
industry-defining merger and acquisition transactions, as well as many
other strategic matters across the biopharmaceutical industry. Mr.
Dickinson received his bachelor’s degree in molecular, cellular and
developmental biology from the University of Colorado and his law degree
from Loyola University Chicago.
“Andy has brought to Gilead vision, creativity and leadership,
fundamentally changing the way that we assess and execute acquisitions
and partnerships as an organization,” said John F. Milligan, PhD,
President and Chief Executive Officer of Gilead. “His deep understanding
of the industry has helped guide Gilead’s strategy and will be critical
to our future success.”
Dr. Silverstein will remain at Gilead through the end of August, working
with Mr. Dickinson and other leaders to transition his duties.
“I’m grateful to Marty for his exceptional work to strengthen Gilead’s
strategic planning and vision, and ensure that we are well-positioned
for future growth, as we seek to bring the next generation of medicines
forward for patients with unmet medical needs,” said Dr. Milligan. “We
understand his decision to eliminate the bicoastal schedule he has kept
since joining Gilead and be closer to his family, and wish him the very
best in the next phase of his career.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters in
Foster City, California.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties, and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended March 31, 2018, as filed with
the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180604006286/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792